Assenagon Asset Management’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $289M | Buy |
2,287,888
+1,775,452
| +346% | +$234M | 0.36% | 46 |
|
|
2026
Q1 | $71.4M | Buy |
512,436
+245,382
| +92% | +$34.4M | 0.11% | 148 |
|
|
2025
Q4 | $32.8M | Sell |
267,054
-3,222,008
| -92% | -$392M | 0.05% | 281 |
|
|
2025
Q3 | $387M | Buy |
3,489,062
+2,169,266
| +164% | +$247M | 0.53% | 35 |
|
|
2025
Q2 | $146M | Buy |
1,319,796
+958,202
| +265% | +$102M | 0.22% | 93 |
|
|
2025
Q1 | $40.5M | Sell |
361,594
-223,482
| -38% | -$23.1M | 0.07% | 240 |
|
|
2024
Q4 | $54M | Sell |
585,076
-1,752,641
| -75% | -$158M | 0.09% | 194 |
|
|
2024
Q3 | $196M | Buy |
2,337,717
+1,437,842
| +160% | +$110M | 0.36% | 49 |
|
|
2024
Q2 | $61.7M | Sell |
899,875
-610,405
| -40% | -$40.7M | 0.14% | 118 |
|
|
2024
Q1 | $111M | Buy |
1,510,280
+1,195,507
| +380% | +$91.9M | 0.26% | 74 |
|
|
2023
Q4 | $25.5M | Sell |
314,773
-317,901
| -50% | -$24.7M | 0.07% | 237 |
|
|
2023
Q3 | $47.4M | Buy |
632,674
+307,785
| +95% | +$23.7M | 0.15% | 123 |
|
|
2023
Q2 | $25M | Sell |
324,889
-426,282
| -57% | -$34M | 0.09% | 190 |
|
|
2023
Q1 | $62.3M | Sell |
751,171
-31,814
| -4% | -$2.63M | 0.22% | 84 |
|
|
2022
Q4 | $67.2M | Sell |
782,985
-897,675
| -53% | -$71.1M | 0.24% | 93 |
|
|
2022
Q3 | $104M | Buy |
1,680,660
+1,262,303
| +302% | +$79.6M | 0.4% | 53 |
|
|
2022
Q2 | $25.9M | Sell |
418,357
-427,715
| -51% | -$26.5M | 0.1% | 190 |
|
|
2022
Q1 | $50.3M | Sell |
846,072
-237,202
| -22% | -$15.2M | 0.14% | 129 |
|
|
2021
Q4 | $78.7M | Buy |
1,083,274
+150,027
| +16% | +$10.3M | 0.23% | 77 |
|
|
2021
Q3 | $65.2M | Buy |
933,247
+903,494
| +3,037% | +$63.5M | 0.21% | 91 |
|
|
2021
Q2 | $2.05M | Sell |
29,753
-227,280
| -88% | -$15.2M | 0.01% | 664 |
|
|
2021
Q1 | $16.6M | Sell |
257,033
-561,768
| -69% | -$36.2M | 0.07% | 241 |
|
|
2020
Q4 | $47.7M | Buy |
818,801
+799,738
| +4,195% | +$48.3M | 0.21% | 97 |
|
|
2020
Q3 | $1.21M | Sell |
19,063
-19,766
| -51% | -$1.37M | 0.01% | 736 |
|
|
2020
Q2 | $2.99M | Sell |
38,829
-297,721
| -88% | -$22.8M | 0.02% | 468 |
|
|
2020
Q1 | $25.2M | Sell |
336,550
-865,124
| -72% | -$59.8M | 0.2% | 85 |
|
|
2019
Q4 | $78.1M | Buy |
1,201,674
+560,774
| +87% | +$36.5M | 0.49% | 43 |
|
|
2019
Q3 | $40.6M | Sell |
640,900
-201,096
| -24% | -$13.1M | 0.27% | 75 |
|
|
2019
Q2 | $56.9M | Buy |
841,996
+669,035
| +387% | +$44M | 0.43% | 50 |
|
|
2019
Q1 | $11.2M | Sell |
172,961
-601,098
| -78% | -$40M | 0.11% | 178 |
|
|
2018
Q4 | $48.4M | Buy |
774,059
+633,699
| +451% | +$44.3M | 0.55% | 48 |
|
|
2018
Q3 | $10.8M | Sell |
140,360
-365,689
| -72% | -$27.6M | 0.11% | 177 |
|
|
2018
Q2 | $35.8M | Buy |
506,049
+297,098
| +142% | +$21M | 0.41% | 68 |
|
|
2018
Q1 | $15.8M | Buy |
208,951
+188,050
| +900% | +$14.9M | 0.21% | 120 |
|
|
2017
Q4 | $1.5M | Sell |
20,901
-859,463
| -98% | -$65.3M | 0.02% | 475 |
|
|
2017
Q3 | $71.3M | Buy |
880,364
+868,784
| +7,502% | +$66.4M | 0.66% | 43 |
|
|
2017
Q2 | $820K | Buy |
+11,580
| New | +$771K | 0.02% | 165 |
|
Other funds holding GILD
Assenagon Asset Management's GILD Position: Q2 2026 in Review
Assenagon Asset Management increased its Gilead Sciences (GILD) stake by 346% in Q2 2026, buying an estimated $234M and bringing the position to 2,287,888 shares worth $289M. The position accounts for 0.36% of the portfolio, ranked #46.
Assenagon Asset Management first reported a position in GILD in Q2 2017 and has held it in 37 quarters since. The position peaked at $387M in Q3 2025. 2,272 funds tracked by Wall St. Rank hold GILD as of Q2 2026.
- Assenagon Asset Management held 2,287,888 shares of Gilead Sciences worth $289M as of Q2 2026.
- Assenagon Asset Management bought 1,775,452 Gilead Sciences shares in Q2 2026, an estimated $234M.
- Gilead Sciences made up 0.36% of Assenagon Asset Management's portfolio in Q2 2026, its #46 holding.
- Assenagon Asset Management first reported a position in Gilead Sciences in Q2 2017 and has held it in 37 quarters since.
- Assenagon Asset Management's Gilead Sciences position peaked at $387M in Q3 2025.
- 2,272 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.
Based on Assenagon Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.